Trials / Completed
CompletedNCT01051414
An Anti-viral Combination Study With Japanese Hepatitis C Infection (HCV) Subject
A Phase 2a Study of BMS-790052 and BMS-650032 in Combination Therapy With Japanese Subjects With Genotype 1 Chronic Hepatitis C (HCV) Virus Infection
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 43 (actual)
- Sponsor
- Bristol-Myers Squibb · Industry
- Sex
- All
- Age
- 20 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
To assess the efficacy and safety profile of co-administration of BMS-790052 and BMS-650032 for 24 weeks treatment.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BMS-790052 | Tablets, Oral, 60 mg, daily, 24 weeks |
| DRUG | BMS-650032 | Tablets, Oral, 1200 mg, daily, 24 weeks |
Timeline
- Start date
- 2010-04-01
- Primary completion
- 2011-09-01
- Completion
- 2012-05-01
- First posted
- 2010-01-18
- Last updated
- 2015-10-09
Locations
4 sites across 1 country: Japan
Source: ClinicalTrials.gov record NCT01051414. Inclusion in this directory is not an endorsement.